UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 187 filers reported holding UNIQURE NV in Q4 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $5,837,000 | -17.6% | 158,479 | +0.8% | 0.14% | -29.1% |
| Q2 2020 | $7,087,000 | -4.3% | 157,282 | +0.8% | 0.20% | -37.6% |
| Q1 2020 | $7,406,000 | -32.0% | 156,076 | +2.6% | 0.32% | -22.4% |
| Q4 2019 | $10,899,000 | +91.1% | 152,096 | +5.0% | 0.41% | +21.2% |
| Q3 2019 | $5,704,000 | -49.5% | 144,909 | +0.2% | 0.34% | -43.9% |
| Q2 2019 | $11,300,000 | +23.0% | 144,595 | -6.1% | 0.60% | -3.7% |
| Q1 2019 | $9,190,000 | -31.0% | 154,058 | -66.6% | 0.63% | -49.4% |
| Q4 2018 | $13,310,000 | -14.7% | 461,837 | +7.7% | 1.24% | +32.5% |
| Q3 2018 | $15,611,000 | +0.9% | 428,980 | +4.8% | 0.94% | -16.2% |
| Q2 2018 | $15,474,000 | +61.9% | 409,370 | +0.7% | 1.12% | +22.6% |
| Q1 2018 | $9,557,000 | +20.9% | 406,667 | +0.8% | 0.91% | -31.0% |
| Q4 2017 | $7,905,000 | – | 403,524 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |